Conference Coverage (ICAAC)

SQ IL-2 + HAART: The Key to HIV Control?

Published in AIDS Weekly, October 18th, 1999

Interleukin 2 (IL-2) may be the push the immune system needs to roll over HIV.

When given together with highly active antiretroviral therapy (HAART), daily subcutaneous (SQ) IL-2 boosts T-cell and natural-killer (NK) cell counts, a new study confirms. Even more exciting are data suggesting that IL-2 given in this context can restore lost immunity to HIV to the degree that a patient could stop taking HAART and avoid the drugs' side effects.

E.L. Jacobson and colleagues of Cornell University, New York, set up a protocol in which patients added SQ IL-2 to their HAART regimens. Some of the patients are scheduled to stop taking HAART when their T-cell...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1999-10-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry